OMER - Omeros Corporation logo

Omeros Corporation

OMER

Omeros Corporation is a clinical-stage biopharmaceutical company that develops small-molecule and protein therapeutics targeting immunologic diseases, including treatments for thrombotic microangiopathy, COVID-19, and various disorders related to MASP-2.

βš•οΈ Healthcare NASDAQ Listed 2009 $ USD
$1,000 invested 10 years ago β†’$1,979today

Score Overview

1 Year
Scoreβ€”
Net Growth39x
Net TrendGrew
Net Income Consistencyβ€”
Rev Growthβ€”
Rev TrendGrew
Revenue Consistencyβ€”
5 Years
Score5.0
Net Growth212.04%
Net Trend60%
Net Income Consistencyβ€”
Rev Growth-89.07%
Rev Trend20%
Revenue Consistencyβ€”
10 Years
Score
Net Growth287.02%
Net Trend60%
Net Income Consistency
Rev Growth-76.23%
Rev Trend40%
Revenue Consistency
All Time
Score
Net Growth7x
Net Trend47%
Net Income Consistency
Rev Growth6x
Rev Trend53%
Revenue Consistency

Explore the 2021 public Archive ranking β†’

Where Omeros Corporation has ranked, year by year

Measure
Fundamentals Window

Showing 10 years ranking history by HDB Score.

Has not reached the top 50 on HDB Score in any year we have ranked.

  • OMER

2020: 85.7% Β· 2021: 84.0% Β· free through 2021 Β· longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-22
$ 16.86β€”
1 Year2025-10-22
$ 7.74117.83%
5 Years2021-10-22
$ 6.49159.78%
10 Years2016-10-21
$ 8.5297.89%
All Time2009-10-08
$ 8.7393.13%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 9M$ 124M$ 131M
2025$ 0.00-$ 3M$ 171M
2024$ 0.00-$ 156M$ 90M
2023$ 0.00-$ 117M$ 171M
2022$ 0.00$ 47M$ 194M
2021$ 90M-$ 111M$ 157M
2020$ 73M-$ 138M$ 134M
2019$ 111M-$ 84M$ 60M
2018$ 29M-$ 126M$ 60M
2017$ 64M-$ 53M$ 83M
2016$ 41M-$ 66M$ 45M
2015$ 13M-$ 75M$ 28M
2014$ 539K-$ 73M$ 6M
2013$ 1M-$ 39M$ 14M
2012$ 6M-$ 38M$ 22M
2011$ 4M-$ 28M$ 24M
2010$ 2M-$ 29M$ 41M
IPO2009$ 1M-$ 21M$ 60M
OMER - Omeros Corporation logo

Omeros Corporation fundamental performance

Between 2020 and 2025, revenue declined from $ 73M to $ 0.00 and net income went from -$ 138M to -$ 3M. Revenue increased in 1 of those 5 years; net income in 3.

Across Omeros Corporation's full reported history, from 2009 to 2025, revenue declined from $ 1M to $ 0.00 and net income went from -$ 21M to -$ 3M. Revenue increased in 53% of the years measured; net income in 47%.

Omeros Corporation currently holds a 5-year HDB Score of 5.0 out of 10. How the HDB Score is calculated.

Membership

Continue OMER’s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,119 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year Β· Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies